Sleep, Obesity and Mental Disease - Biological Markers for the Evaluation of Circadian Rhythmicity (SOMBER)

January 4, 2024 updated by: Hospital of South West Jutland

Circadian Disturbances in People With Mental Disease

Introduction

16.8% of the Danish adult population are obese (Body Mass Index> 30 kg / m2). Obesity increases the risk of lifestyle diseases such as type-2 diabetes and non-alcoholic fatty liver. People with mental illness have an increased risk of developing obesity. Both obesity and certain mental disorders (bipolar disorder and schizophrenia) are associated with circadian rhythm disorders. Clinically, this may manifest as reduced sleep quality, depressive symptoms and increased fatigue, but also deregulation of a wide range of bodily processes subject to the circadian rhythm.

In circadian rhythm disorders, the pattern of how mRNA of specific 'clock genes' is expressed in the cell may be affected. These clock genes are associated with obesity, bipolar disorder and schizophrenia. Despite the clear indications of an interplay between mental illness, obesity and circadian rhythm disorders, the relationship between these illnesses are largely unexplored.

Aim

The aim of this study is to investigate circadian disturbances in people with and without obesity, as well as people with obesity and a comorbid diagnosis of either schizophrenia or bipolar disorder.

Methods

The study population will consist of:

  1. People with obesity and schizophrenia (N=22)
  2. People with obesity and bipolar disorder (N=22)
  3. People with obesity without psychiatric disease (N=22)
  4. People with BMI 18.5 - 25kg/m2 and no psychiatric disease (N=20)

Study Procedure

Participants will visit the clinic 2 times. At each visit participants fill in questionnaires and perform physical tests. Between visit 1 and 2, participants will over a 2-day period (at-home), collect biological samples (Four hair- and six saliva samples per day). In addition, participants will wear accelerometers and continuous glucose monitors (CGMs) for a total of 8 days, including the 2-day sampling period.

Sampled hair follicles are analyzed for relative expression of clock gene mRNA. Saliva is analyzed for cortisol- and melatonin content. The four participants groups are analyzed and compared on daytime variation in mRNA expression, cortisol- and melatonin concentration, and body temperature.

Perspectives

A comparison of patient groups presenting with mental disease, obesity and circadian disturbances may provide new insight into the association between these diseases.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Background

Obesity (30 ≥ kg/m2) is a major global health challenge. Worldwide obesity has nearly tripled since 1975 (WHO, 2021) and is projected to continue to rise throughout western society (OECD, 2017).

Obesity increases the risk of type-2 diabetes (T2D), obstructive sleep apnea (OSA), non-alcoholic fatty liver disease (NAFLD), hypertension, osteoarthritis, polycystic ovary syndrome and several other conditions (George et al., 2018; Luque-Ramirez et al., 2014; Mainous, Tanner, Jo, & Anton, 2016). Mortality is significantly increased, and a person with class III obesity (BMI > 40kg/m2) is predicted to live ten years shorter than a normal-weight person of same age (Finkelstein, Brown, Wrage, Allaire, & Hoerger, 2010). People with obesity have more days of sick leave, experience social disadvantages (Hernaes, Andersen, Norheim, & Vage, 2015) and report an overall poorer health-related quality of life compared to non-obese people (Kolotkin & Andersen, 2017).

Obesity and mental disease:

Mental disease is associated with increased risk of obesity. Obesity is approximately two and three times as prevalent in people with bipolar disorders and schizophrenia spectrum disorder compared to people without mental disease, respectively (Annamalai, Kosir, & Tek, 2017; Chao, Wadden, & Berkowitz, 2019; Sicras, Rejas, Navarro, Serrat, & Blanca, 2008). Many commonly used antipsychotic drugs induces weight gain with a magnitude ranging from neutral in some drugs to +5.3 kg in olanzapine (Vancampfort et al., 2015). Antipsychotic-induced weight changes depend of the underlying disease (Moteshafi, Zhornitsky, Brunelle, & Stip, 2012). Many mental diseases are associated with higher calorie intake, poorer food quality (Manu et al., 2015) and lower levels of physical activity (Schuch et al., 2017; Vancampfort et al., 2017).

Obesity, mental disease and circadian disturbances:

The human body adapts cellular, physiological, and behavioral rhythms to the 24-hour light cycle. Disturbing the normal circadian rhythms have dramatic consequences on many health issues ranging from cardiovascular disease to cancer (Morris, Purvis, Hu, & Scheer, 2016; Stevens, Brainard, Blask, Lockley, & Motta, 2014). A sleep pattern concordant with the diurnal rhythm is crucial for maintaining normal body weight. Sleeping incoherently with the circadian-defined sleep hours thus independently associates with overweight and obesity, increasing the relative risk by 31% and 96% respectively (McFadden, Jones, Schoemaker, Ashworth, & Swerdlow, 2014). In people with schizophrenia and bipolar disorders almost all measures of sleep quality and physiological sleep patterns are disturbed, even when their disease is considered well-treated (Meyer et al., 2020).

In human cells, circadian clocks are composed of a set of proteins that generate self-sustained circadian oscillation through positive and negative transcriptional/translational feedback loops. The human circadian clock entails a range of 'clock genes'. For example: The 'Period' genes (per1 and per2) are both parts of the circadian feedback loop. Mice models knocked out for per1/2 completely lacks a diurnal rhythm and gain more weight following a high-fat diet (Dallmann & Weaver, 2010). Dysregulation of per1, per2 and other clock genes have been linked to psychiatric disorders, including depression, schizophrenia and bipolar disorders (Charrier, Olliac, Roubertoux, & Tordjman, 2017).

Altogether disturbance in clock-gene and hormonal rhythmicity might be an important link between mental disease, sleep disturbance and obesity. Sleep disturbances are potentially treatable. Accordingly, restoration of sleep patterns might be a possible target to prevent weight gain and obesity in this group of patients.

Study aim:

To evaluate biological markers of disturbed circadian rhythm in people with obesity and schizophrenia or bipolar disorder.

Overall hypotheses:

People with obesity and schizophrenia or bipolar disorder has disturbed circadian rhythms compared to controls without mental disease.

Methods

Study design:

This will be a single-center case-control study with repeated measures.

Study Population:

The study population will consist of four groups:

  1. People with BMI > 30 kg/m2 and schizophrenia spectrum disorder (N=22)
  2. People with BMI > 30 kg/m2 and bipolar spectrum disorder (N=22)
  3. People with BMI > 30 kg/m2 without psychiatric disease or sleep disorders (N=22)
  4. People with BMI 18.5 - 25kg/m2 and no psychiatric disease or sleep disorders (N=20)

Exclusion criterion:

• Participants taking oral supplements of melatonin are excluded if pausing is deemed inappropriate.

Study Procedure:

Participants will visit the clinic two times. Between visits, participants will collect biological samples and data relevant to understanding circadian rhythms over a 2-day period. In addition participants will wear accelerometers and continuous glucose monitors (CGMs) for a total of 8 days.

Clinical visit 1:

During the first clinical visit, a short (<10 min) test battery will be administered. This includes tests of gait function, handgrip strength and balance. In addition weight, height, waist- and hip circumference and body composition (by bioimpedance) are measured. After tests, a short questionnaire is administered.

Finally, body worn sensors (accelerometers and CGMs) are mounted, and the participant is given thorough instruction on how to record dietary intake and perform biological sampling (hair and saliva samples). The two sampling days will, when possible, be placed immediately following clinical visit 1 and at least within 5 days.

At-home testing:

During test day 1 and 2, participants will collect saliva samples ~6 times (depended on bed time) per day and hair samples 4 times per day and record their body temperature and dietary food intake (see "data collection" below). Participants will each day receive home visits from the project manager. If possible, visits will be scheduled around noon in order to aid participants with mid-day sampling. Visits are scheduled to take <20 minutes. During visits, the project manager will administer a short questionnaire on media device usage and sleep environment light exposure.

Clinical visit 2:

Following the two sampling days, participants will again meet at the clinic. During this visit, remaining test equipment and samples are handed over. Afterwards, the patient fills in the Morningness-Eveningness Questionnaire (MEQ). In addition, the test leader will perform a short interview (~10 min) in which participants are asked to rate their experience. If the participant have not been screened for sleep apnea recently (<6months), a time for respiratory sleep monitoring will be scheduled.

Data handling and analyses:

Data will be hosted and handled in accordance with Danish law and regulation. All data Files will be kept for 5 years following study conclusion and subsequently anonymized or deleted.

Statistics:

Disturbances in circadian rhythm will be analyzed by multi-level longitudinal analyses comparing findings between study groups (BMI >30 kg/m2, ≤25 kg/m2, with and without mental disease) adjusted for gender and age. Associations between circadian regulated variables (hormones, temperature, glucose levels and gene expression) will be investigated by correlational analysis.

Power calculation:

Being explorative in nature, there is insufficient data to conduct a candid power-calculation. However recent studies detected significant differences in clock-gene expression between people with and without sleep disturbances with 14 to 20 people in each study group (Canales et al., 2019; Zhanfeng, Hechun, Zhijun, Hongyu, & Zhou, 2019).

Information from patient registries:

After consent is signed, patient journals will be reviewed for information on age, gender, socioeconomic status, medication status and the presence of psychiatric diagnoses (Bi-polar, schizophrenia and depression), medication history and obesity-related disease prevalence.

Financing and insurance:

This is an investigator initiated research project. The Project received 913.000 kr.- from Region Syddanmarks pulje for Fri og Strategisk Forskning 2021 to cover running expenses. Study funds are placed on a dedicated account and the account number has been disseminated to the Regional Committee on Health Research Ethics for Southern Denmark. The investigators or The Department of Medicine, University Hospital South West Jutland have no financial gain regarding the study and have no conflict of interest that could be perceived as prejudicing the impartiality of this study. The patients will not receive payment but reimbursement of travel expenses can be made.

Side effects, risks and complications:

The study is designed to minimize inconvenience by employing a relative short list of outcomes requiring active participant involvement. Moreover, participant work loads are minimized through the use of digital solutions. Participants are not required to record sleep or food diaries and do not need to weigh food items as these are recorded by digital camera.

There are no known risks associated with present study procedure. Participants are informed of potential discomfort when plucking hairs or when mounting the CGM and that some may experience poorer sleep quality when sleeping with the CRM instrument. Participants are encouraged to report any adverse events experienced during or following the study procedure. In case of injury participant are instructed to report their case to the Danish national patient compensation scheme (http://www.patientforsikringen.dk), also linked in the participant information.

Perspectives

Comparative data on patient groups presenting with mental disease, obesity and circadian disturbances may help elucidate the association between these diseases. If circadian disturbances are more pronounced in people with obesity and schizophrenia or bipolar disorder, compared to people with obesity and no mental disease, this highlights the need for treatment effective in normalizing sleep patterns in these patient groups.

Study Type

Observational

Enrollment (Estimated)

86

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 60 years (Adult)

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

Participants may be recruited by two pathways:

  1. Referral through psychiatric treatment units*

  2. Referral through the South Danish Obesity initiative (SDOI)

    • In addition to local treatment clinics this includes the following collabarative networks: OPT (Opsøgende Psykoseteam (english: outreach Psychosis team)), OPUS (Opsøgende Psykoseteam for Unge med Skizofreni (english: outreach Psychosis team for young adults with schizophrenia) and Psykinfo (a mental health information service in the Region of Southern Denmark).

A third pathway is available for healthy controls: Posters are placed in libraries, groceries and educational facilities and by advertising in select local Facebook groups, especially targeting young (>30 years) adults.

While no formal exclussion criteria is presented regarding symptom severity. Health workers at psychiatric treatment units and SDOI will only refer participants with a high propability of completing the examination program.

Description

Inclusion Criteria:

Fulfilling the criteria for one of the four study groups:

  • People with BMI > 30 kg/m2 and schizophrenia spectrum disorder (N=22)
  • People with BMI > 30 kg/m2 and bipolar disorder spectrum disorder (N=22)
  • People with BMI > 30 kg/m2 without psychiatric disease or sleep disorders (N=22)
  • People with BMI 18.5 - 25kg/m2 and no psychiatric disease or sleep disorders (N=20)

Exclusion Criteria:

  • Participants taking oral supplements of melatonin are excluded if pausing is deemed inappropriate.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
SCH, OB
People with obesity (BMI > 30 kg/m2) and a medical diagnosis of schizophrenia spectrum disorder.
Other: Observational

Exposure is defined by group affiliation i.e., Bipolar disorder vs. schizophrenia vs. no disease. Likewise with obesity vs. normal weight.

Biological markers of daytime-circadian rhythmicity is compared across disease and weight groups.
BD, OB
People with obesity (BMI > 30 kg/m2) and a medical diagnosis of bipolar spectrum disorder.
Other: Observational

Exposure is defined by group affiliation i.e., Bipolar disorder vs. schizophrenia vs. no disease. Likewise with obesity vs. normal weight.

Biological markers of daytime-circadian rhythmicity is compared across disease and weight groups.
Control, OB
Control group with obesity. People with obesity (BMI > 30 kg/m2) without psychiatric disease or sleep disorders.
Other: Observational

Exposure is defined by group affiliation i.e., Bipolar disorder vs. schizophrenia vs. no disease. Likewise with obesity vs. normal weight.

Biological markers of daytime-circadian rhythmicity is compared across disease and weight groups.
Control, non-OB
Normal weight (BMI 18.5 - 25kg/m2) control group without psychiatric disease.
Other: Observational

Exposure is defined by group affiliation i.e., Bipolar disorder vs. schizophrenia vs. no disease. Likewise with obesity vs. normal weight.

Biological markers of daytime-circadian rhythmicity is compared across disease and weight groups.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Daytime Circadian variation in clock gene mRNA expression
Time Frame: for two full consecutive days participant will pluck hairs and place the hair root in a dissolution buffer. Participants will each collect 4 samples per day: immediately after waking, and every 6th preceding hour, including immediately before bed.
Relative amount of different clock gene mRNA, compared to housekeeping gene
for two full consecutive days participant will pluck hairs and place the hair root in a dissolution buffer. Participants will each collect 4 samples per day: immediately after waking, and every 6th preceding hour, including immediately before bed.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Daytime Circadian variation in saliva melatonin concentration
Time Frame: for two full consecutive days participant will collect saliva samples. Participants will each collect ~6 samples per day: immediately after waking, 6 and 12 hours after waking and every 2 hours until bedtime, including a sample immediately before bed.
Saliva samples are analyzed for melatonin concentration throughout the day.
for two full consecutive days participant will collect saliva samples. Participants will each collect ~6 samples per day: immediately after waking, 6 and 12 hours after waking and every 2 hours until bedtime, including a sample immediately before bed.
Daytime Circadian variation in saliva cortisol concentration
Time Frame: for two full consecutive days participant will collect saliva samples. Participants will each collect ~6 samples per day: immediately after waking, 6 and 12 hours after waking and every 2 hours until bedtime, including a sample immediately before bed.
Saliva samples are analyzed for cortisol concentration throughout the day.
for two full consecutive days participant will collect saliva samples. Participants will each collect ~6 samples per day: immediately after waking, 6 and 12 hours after waking and every 2 hours until bedtime, including a sample immediately before bed.

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Sleep amount and quality
Time Frame: Participant will wear accelerometers for 8 consecutive days. The two self-sampling days and an additional 6 days.
assessed by accelerometry (placement: right thigh and non-dominant wrist)
Participant will wear accelerometers for 8 consecutive days. The two self-sampling days and an additional 6 days.
Continous glucose monitoring
Time Frame: Participant will wear glucose monitors for 8 consecutive days. The two self-sampling days and an additional 6 days.
glucose levels are monitored using a body-worn monitor (freestyle libre)
Participant will wear glucose monitors for 8 consecutive days. The two self-sampling days and an additional 6 days.
Dietary intake and timing
Time Frame: Participants will record dietary items for two consecutive days (the two self-sampling days)
Timing of food consumption, total caloric intake and caloric distribution (fat, protein, carbohydrates) will be estimated using a digital food diary
Participants will record dietary items for two consecutive days (the two self-sampling days)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Hospital of South West Jutland

Collaborators

Odense University Hospital
Rigshospitalet, Denmark
University of Southern Denmark
Odense Patient Data Explorative Network
Steno Diabetes Center Odense
Mental Health Services in the Region of Southern Denmark

Investigators

  • Principal Investigator: Claus B Juhl, University Hospital South West Jutland, Department of Endocrinology

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 4, 2022

Primary Completion (Estimated)

July 31, 2024

Study Completion (Estimated)

July 31, 2024

Study Registration Dates

First Submitted

June 7, 2022

First Submitted That Met QC Criteria

June 7, 2022

First Posted (Actual)

June 10, 2022

Study Record Updates

Last Update Posted (Actual)

January 5, 2024

Last Update Submitted That Met QC Criteria

January 4, 2024

Last Verified

January 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 21/61643

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Sharing of IPD is under current Danish law not feasible.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Obesity

Clinical Trials on Observational

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Armenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe